Overview of pharmacological interventions after traumatic brain injuries: impact on selected outcomes

Sonya Kim, Marianne Mortera, Xiaolei Hu, Shilpa Krishnan, Lilian Hoffecker, Amy Herrold, Lauren Terhorst, Laurie King, Joseph Machtinger, Jennifer M. Zumsteg, Ahmed Negm, Patricia Heyn

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to conduct an overview of systematic reviews (SRs) to appraise the published evidence related to pharmacological interventions after traumatic brain injury (TBI). Searches were conducted with Medline, Embase, PsycINFO, Web of Science, PubMed. 780 retrieved SRs underwent a two-level screening to determine inclusion. Data extracted included participant characteristics, TBI severity, study design, pharmacological interventions, and outcomes. SRs were assessed for methodological quality by using the AMSTAR measurement tool. After removing duplicates, 166/780 SRs published between 1990-2017 were reviewed, 62 of which met inclusion criteria. More than 90 drugs and 22 substance-classes were extracted. Most medications were administered during the acute stage. Mild TBI was included in 3% of the SRs. Physiological outcomes comprised 45% of the SRs, primarily mortality. Activities of daily living (ADLs) outcomes constituted 22% of the SRs followed by cognition (13%) and psychological/behavioral outcomes (13%). Only 7% of the SRs assessed adverse events. Inconsistencies in definitions, methods, and heterogeneity of instruments used to measure treatment response were noted. Only a third of the SRs had high methodological quality. Most SRs had heterogeneous TBI samples, outcomes, or methodologies making it difficult to synthesize findings into recommended guidelines. This study demonstrated a need for adequately powered and rigorous randomized clinical trials (RCTs) to provide generalizable evidence on the effectiveness of pharmacologic interventions for TBI. PROSPERO Registration: CRD42015017355.

Original languageEnglish (US)
Pages (from-to)442-455
Number of pages14
JournalBrain Injury
Volume33
Issue number4
DOIs
StatePublished - Mar 21 2019

Fingerprint

Pharmacology
Brain Concussion
Activities of Daily Living
PubMed
Cognition
Randomized Controlled Trials
Guidelines
Psychology
Mortality
Traumatic Brain Injury
Pharmaceutical Preparations
Therapeutics

Keywords

  • meta-analysis
  • pharmacological interventions
  • Systematic review
  • traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Developmental and Educational Psychology
  • Clinical Neurology

Cite this

Kim, S., Mortera, M., Hu, X., Krishnan, S., Hoffecker, L., Herrold, A., ... Heyn, P. (2019). Overview of pharmacological interventions after traumatic brain injuries: impact on selected outcomes. Brain Injury, 33(4), 442-455. https://doi.org/10.1080/02699052.2019.1565896

Overview of pharmacological interventions after traumatic brain injuries : impact on selected outcomes. / Kim, Sonya; Mortera, Marianne; Hu, Xiaolei; Krishnan, Shilpa; Hoffecker, Lilian; Herrold, Amy; Terhorst, Lauren; King, Laurie; Machtinger, Joseph; Zumsteg, Jennifer M.; Negm, Ahmed; Heyn, Patricia.

In: Brain Injury, Vol. 33, No. 4, 21.03.2019, p. 442-455.

Research output: Contribution to journalArticle

Kim, S, Mortera, M, Hu, X, Krishnan, S, Hoffecker, L, Herrold, A, Terhorst, L, King, L, Machtinger, J, Zumsteg, JM, Negm, A & Heyn, P 2019, 'Overview of pharmacological interventions after traumatic brain injuries: impact on selected outcomes', Brain Injury, vol. 33, no. 4, pp. 442-455. https://doi.org/10.1080/02699052.2019.1565896
Kim, Sonya ; Mortera, Marianne ; Hu, Xiaolei ; Krishnan, Shilpa ; Hoffecker, Lilian ; Herrold, Amy ; Terhorst, Lauren ; King, Laurie ; Machtinger, Joseph ; Zumsteg, Jennifer M. ; Negm, Ahmed ; Heyn, Patricia. / Overview of pharmacological interventions after traumatic brain injuries : impact on selected outcomes. In: Brain Injury. 2019 ; Vol. 33, No. 4. pp. 442-455.
@article{c8402fb565e14b44be8338b8ca38d1b4,
title = "Overview of pharmacological interventions after traumatic brain injuries: impact on selected outcomes",
abstract = "The purpose of this study was to conduct an overview of systematic reviews (SRs) to appraise the published evidence related to pharmacological interventions after traumatic brain injury (TBI). Searches were conducted with Medline, Embase, PsycINFO, Web of Science, PubMed. 780 retrieved SRs underwent a two-level screening to determine inclusion. Data extracted included participant characteristics, TBI severity, study design, pharmacological interventions, and outcomes. SRs were assessed for methodological quality by using the AMSTAR measurement tool. After removing duplicates, 166/780 SRs published between 1990-2017 were reviewed, 62 of which met inclusion criteria. More than 90 drugs and 22 substance-classes were extracted. Most medications were administered during the acute stage. Mild TBI was included in 3{\%} of the SRs. Physiological outcomes comprised 45{\%} of the SRs, primarily mortality. Activities of daily living (ADLs) outcomes constituted 22{\%} of the SRs followed by cognition (13{\%}) and psychological/behavioral outcomes (13{\%}). Only 7{\%} of the SRs assessed adverse events. Inconsistencies in definitions, methods, and heterogeneity of instruments used to measure treatment response were noted. Only a third of the SRs had high methodological quality. Most SRs had heterogeneous TBI samples, outcomes, or methodologies making it difficult to synthesize findings into recommended guidelines. This study demonstrated a need for adequately powered and rigorous randomized clinical trials (RCTs) to provide generalizable evidence on the effectiveness of pharmacologic interventions for TBI. PROSPERO Registration: CRD42015017355.",
keywords = "meta-analysis, pharmacological interventions, Systematic review, traumatic brain injury",
author = "Sonya Kim and Marianne Mortera and Xiaolei Hu and Shilpa Krishnan and Lilian Hoffecker and Amy Herrold and Lauren Terhorst and Laurie King and Joseph Machtinger and Zumsteg, {Jennifer M.} and Ahmed Negm and Patricia Heyn",
year = "2019",
month = "3",
day = "21",
doi = "10.1080/02699052.2019.1565896",
language = "English (US)",
volume = "33",
pages = "442--455",
journal = "Brain Injury",
issn = "0269-9052",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Overview of pharmacological interventions after traumatic brain injuries

T2 - impact on selected outcomes

AU - Kim, Sonya

AU - Mortera, Marianne

AU - Hu, Xiaolei

AU - Krishnan, Shilpa

AU - Hoffecker, Lilian

AU - Herrold, Amy

AU - Terhorst, Lauren

AU - King, Laurie

AU - Machtinger, Joseph

AU - Zumsteg, Jennifer M.

AU - Negm, Ahmed

AU - Heyn, Patricia

PY - 2019/3/21

Y1 - 2019/3/21

N2 - The purpose of this study was to conduct an overview of systematic reviews (SRs) to appraise the published evidence related to pharmacological interventions after traumatic brain injury (TBI). Searches were conducted with Medline, Embase, PsycINFO, Web of Science, PubMed. 780 retrieved SRs underwent a two-level screening to determine inclusion. Data extracted included participant characteristics, TBI severity, study design, pharmacological interventions, and outcomes. SRs were assessed for methodological quality by using the AMSTAR measurement tool. After removing duplicates, 166/780 SRs published between 1990-2017 were reviewed, 62 of which met inclusion criteria. More than 90 drugs and 22 substance-classes were extracted. Most medications were administered during the acute stage. Mild TBI was included in 3% of the SRs. Physiological outcomes comprised 45% of the SRs, primarily mortality. Activities of daily living (ADLs) outcomes constituted 22% of the SRs followed by cognition (13%) and psychological/behavioral outcomes (13%). Only 7% of the SRs assessed adverse events. Inconsistencies in definitions, methods, and heterogeneity of instruments used to measure treatment response were noted. Only a third of the SRs had high methodological quality. Most SRs had heterogeneous TBI samples, outcomes, or methodologies making it difficult to synthesize findings into recommended guidelines. This study demonstrated a need for adequately powered and rigorous randomized clinical trials (RCTs) to provide generalizable evidence on the effectiveness of pharmacologic interventions for TBI. PROSPERO Registration: CRD42015017355.

AB - The purpose of this study was to conduct an overview of systematic reviews (SRs) to appraise the published evidence related to pharmacological interventions after traumatic brain injury (TBI). Searches were conducted with Medline, Embase, PsycINFO, Web of Science, PubMed. 780 retrieved SRs underwent a two-level screening to determine inclusion. Data extracted included participant characteristics, TBI severity, study design, pharmacological interventions, and outcomes. SRs were assessed for methodological quality by using the AMSTAR measurement tool. After removing duplicates, 166/780 SRs published between 1990-2017 were reviewed, 62 of which met inclusion criteria. More than 90 drugs and 22 substance-classes were extracted. Most medications were administered during the acute stage. Mild TBI was included in 3% of the SRs. Physiological outcomes comprised 45% of the SRs, primarily mortality. Activities of daily living (ADLs) outcomes constituted 22% of the SRs followed by cognition (13%) and psychological/behavioral outcomes (13%). Only 7% of the SRs assessed adverse events. Inconsistencies in definitions, methods, and heterogeneity of instruments used to measure treatment response were noted. Only a third of the SRs had high methodological quality. Most SRs had heterogeneous TBI samples, outcomes, or methodologies making it difficult to synthesize findings into recommended guidelines. This study demonstrated a need for adequately powered and rigorous randomized clinical trials (RCTs) to provide generalizable evidence on the effectiveness of pharmacologic interventions for TBI. PROSPERO Registration: CRD42015017355.

KW - meta-analysis

KW - pharmacological interventions

KW - Systematic review

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85060927619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060927619&partnerID=8YFLogxK

U2 - 10.1080/02699052.2019.1565896

DO - 10.1080/02699052.2019.1565896

M3 - Article

C2 - 30694081

AN - SCOPUS:85060927619

VL - 33

SP - 442

EP - 455

JO - Brain Injury

JF - Brain Injury

SN - 0269-9052

IS - 4

ER -